Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier and get daily trading ideas and historical data downloads. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Eagle Pharmaceuticals Inc (EGRX)

Eagle Pharmaceuticals Inc (EGRX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]

Fundamentals

See More
  • Market Capitalization, $K 23,377
  • Shares Outstanding, K 12,987
  • Annual Sales, $ 316,610 K
  • Annual Income, $ 35,640 K
  • EBIT $ 41 M
  • EBITDA $ 55 M
  • 60-Month Beta 0.83
  • Price/Sales 0.11
  • Price/Cash Flow 0.43
  • Price/Book 0.08
  • Price/Earnings ttm 0.00
  • Earnings Per Share ttm 1.18
  • Most Recent Earnings N/A on 08/08/23
  • Next Earnings Date 01/01/70
  • Annual Dividend & Yield (Fwd) 0.00 (0.00%)
  • Most Recent Dividend N/A on N/A
  • Sector Medical
  • INDUSTRY GROUPING Medical Products

Price Performance

See More
Period Period Low Period High Performance
1-Month
0.1004 +248.61%
on 01/21/26
0.8500 -58.82%
on 01/14/26
+0.0200 (+6.06%)
since 12/26/25
3-Month
0.1004 +248.61%
on 01/21/26
1.8000 -80.56%
on 11/18/25
-0.4000 (-53.33%)
since 10/27/25

Most Recent Stories

More News
Eagle Pharmaceuticals Announces Divestiture of Barhemsys

WOODCLIFF LAKE, N.J., Jan. 14, 2026 (GLOBE NEWSWIRE) -- Eagle Pharmaceuticals, Inc. (OTCMKTS: EGRX) (the “Company” or “Eagle”) is pleased to announce the divestiture of the marketing authorization...

EGRX : 0.3500 (-50.00%)
HALPER SADEH LLC ENCOURAGES EAGLE PHARMACEUTICALS, INC. SHAREHOLDERS TO CONTACT THE FIRM TO DISCUSS THEIR RIGHTS

Shareholders should contact the firm immediately as there may be limited time to enforce your rights.

EGRX : 0.3500 (-50.00%)
Halper Sadeh LLC Encourages Eagle Pharmaceuticals, Inc. Shareholders to Contact the Firm to Discuss Their Rights

Shareholders should contact the firm immediately as there may be limited time to enforce your rights.

EGRX : 0.3500 (-50.00%)
Eagle Pharmaceuticals Board Extends Limited Duration Stockholder Rights Plan

WOODCLIFF LAKE, N.J., Oct. 30, 2025 (GLOBE NEWSWIRE) -- Eagle Pharmaceuticals, Inc. (OTCMKTS: EGRX) (the “Company” or “Eagle”) today announced that its Board of Directors (the “Board”) has...

EGRX : 0.3500 (-50.00%)
Eagle Pharmaceuticals Announces Results of 2025 Annual Meeting of Stockholders

WOODCLIFF LAKE, N.J., Oct. 21, 2025 (GLOBE NEWSWIRE) -- Eagle Pharmaceuticals, Inc. (OTCMKTS: EGRX) (the “Company” or “Eagle”) is pleased to announce the voting results for each of the matters...

EGRX : 0.3500 (-50.00%)
Eagle Pharmaceuticals Announces Availability of Unaudited Second Quarter 2025 Financial Statements

WOODCLIFF LAKE, N.J., Oct. 15, 2025 (GLOBE NEWSWIRE) -- Eagle Pharmaceuticals, Inc. (OTCMKTS: EGRX) (the “Company” or “Eagle”) today announced that the Company’s unaudited financial statements...

EGRX : 0.3500 (-50.00%)
Eagle Pharmaceuticals Announces Availability of Unaudited First Quarter 2025 Financial Statements

WOODCLIFF LAKE, N.J., Oct. 06, 2025 (GLOBE NEWSWIRE) -- Eagle Pharmaceuticals, Inc. (OTCMKTS: EGRX) (the “Company” or “Eagle”) today announced that the Company’s unaudited financial statements...

EGRX : 0.3500 (-50.00%)
Eagle Pharmaceuticals Announces Availability of Proxy Materials and Audited Financial Statements for the 2023 and 2024 Fiscal Years

WOODCLIFF LAKE, N.J., Sept. 17, 2025 (GLOBE NEWSWIRE) -- Eagle Pharmaceuticals, Inc. (OTCMKTS: EGRX) (the “Company” or “Eagle”) today announced the availability of proxy materials for its 2025...

EGRX : 0.3500 (-50.00%)
Eagle Pharmaceuticals to Appoint Abhinav Jain to its Board of Directors

WOODCLIFF LAKE, N.J., Aug. 28, 2025 (GLOBE NEWSWIRE) -- Eagle Pharmaceuticals, Inc. (OTCMKTS: EGRX) (the “Company” or “Eagle”) today announced that it has agreed to appoint Abhinav “Abi”...

EGRX : 0.3500 (-50.00%)
Eagle Pharmaceuticals Announces 2025 Annual Meeting Date

WOODCLIFF LAKE, N.J., Aug. 18, 2025 (GLOBE NEWSWIRE) -- Eagle Pharmaceuticals, Inc. (OTCMKTS: EGRX) (the “Company” or “Eagle”) today announced that its 2025 Annual Meeting of Stockholders (the...

EGRX : 0.3500 (-50.00%)

Business Summary

Eagle Pharmaceuticals, Inc. is a specialty pharmaceutical company. It focuses on developing and commercializing injectable products primarily in the critical care and oncology areas in the United States. The Company markets EP-1101 to treat heparin-induced thrombocytopenia. It develops EP-3101, EP-3102,...

See More

Key Turning Points

3rd Resistance Point 0.3500
2nd Resistance Point 0.3500
1st Resistance Point 0.3500
Last Price 0.3500
1st Support Level 0.3500
2nd Support Level 0.3500
3rd Support Level 0.3500

See More

52-Week High 3.8700
Fibonacci 61.8% 2.4300
Fibonacci 50% 1.9852
Fibonacci 38.2% 1.5404
Last Price 0.3500
52-Week Low 0.1004

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar